22-year-old Mason grad's 90 second heart scan invention awaiting FDA approval
MASON, Ohio (WKRC) - The next big medical breakthrough could be the creation of a Mason man who dropped out of college to start a business.
The newly invented device can detect heart problems in less than two minutes.
Genetesis is a medical device company whose co-founder is just 22-years-old. The company closed its most recent funding stage with $7.5 million in financing with investors like billionaire venture capitalist Marc Cuban and the local firm of Cincy Tech.
Genetesis uses biomagnetic imaging to scan the heart according to co-founder Peeyush Shrivastava.
“Instead of emitting a magnetic field to evaluate the structure of the heart we measure the field naturally generated by the heart to rapidly ruled out coronary artery disease in patients with chest pain,” said Shrivastava.
The device has already gone through a clinical trial with 104 patients at St. John Hospital in Detroit, MI. Now Genetesis is awaiting approval from the Food and Drug Administration to be labeled a class two medical device.
“I was working in the lab and doing a lot of work with isolated heart cells and measure electric currents through those cells,” said Shrivastava. “I realized there was a gap between how we were working in the lab versus how we were treating patients at the clinic. We wanted to create a company that bridged that cap and that’s what Genetesis ended up becoming.”
Surrounded in the company by some of his high school classmates and his dad, Shrivastava is teaming up with some big investors to make the distribution of the device happen.
“If we can radically change cardiac care that’s a big thing,” said Cincy Tech CEO Mike Vernerable.
For Vernerable, just thinking about the time, money and stress a scan like this could save a patient is the key in backing a company like Genetesis.
Shrivastava approached the start up support company when he was just 19-years-old according to Cincy Tech Director of Life Science John Rice.
“The impact they can have is pretty profound,” said Rice. “The ability to greatly speed up the process to determine whether you’re having a heart attack or not is importantly clinically but it’s also important from an economical point of view because it’s a less expensive and more rapid way to get information and make decisions about patients to help more quickly.”
Shrivastava hopes to gain FDA approval this year and have the device in emergency rooms in the next five years.